Advertisement Covers CROI 2017


The Need to Advocate for Fair HIV Drug Prices

March 4, 2017

Drug prices are too high and your access to your drugs is in danger. So, wake up and get ready!

-- Lynda Dee

In an interview on behalf of IFARA at CROI 2017, Fred Schaich spoke with Lynda Dee and Tim Horn about the price of HIV medications and the work of the Fair Pricing Coalition. The organization was formed in response to the initial price of early antiretrovirals. It works to lower the price of drugs when they are first approved by the U.S. Food and Drug Administration, to keep price increases for medications at the consumer price index level and to advocate with governmental bodies for legislative measures on drug pricing.

The cost of almost all antiretrovirals still under patent increases by about 6%-9% per year, well above the rise in the consumer price index, said Tim Horn. He added that the highest expenditure in public health insurance programs, such as Medicaid and Medicare, is medication. The U.S. has a very complex health care delivery and pricing system compared with European systems. While federal policies are important in this respect, much of the health care infrastructure is handled on the state level.

Lynda Dee urged people to make their legislators aware of the effect that medication pricing has on them.

More information about the Fair Pricing Coalition is available at

Watch the video to learn more:

About the panelists:

  • Lynda Dee, Fair Pricing Coalition.
  • Tim Horn, Fair Pricing Coalition.

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Related Stories

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline
CROI Shows the Importance of 90-90-90

This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.